448 related articles for article (PubMed ID: 34074804)
21. Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.
Jeon J; Jang SY; Kwak EJ; Lee SH; Byun JY; Kim YY; Ahn YG; Singh P; Moon K; Kim IS
Eur J Med Chem; 2023 Dec; 261():115840. PubMed ID: 37783102
[TBL] [Abstract][Full Text] [Related]
22. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
23. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple
Zheng Q; Chen D; Wang X; Yang Y; Zhao S; Dong X; Ma C; Zhang X; Duan H; Sun Y; Zheng S
Ann Transl Med; 2022 Jun; 10(12):696. PubMed ID: 35845484
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.
Nagano T; Tachihara M; Nishimura Y
Cells; 2018 Nov; 7(11):. PubMed ID: 30445769
[TBL] [Abstract][Full Text] [Related]
25. Two case reports of non-small cell lung cancer patients harboring acquired
Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
[TBL] [Abstract][Full Text] [Related]
26. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
Du Y; Chen Y; Wang Y; Chen J; Lu X; Zhang L; Li Y; Wang Z; Ye G; Zhang G
Mol Cancer Ther; 2022 Jul; 21(7):1060-1066. PubMed ID: 35499406
[TBL] [Abstract][Full Text] [Related]
27. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
[TBL] [Abstract][Full Text] [Related]
28. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
29. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
31. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
32. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
[TBL] [Abstract][Full Text] [Related]
33. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Andrews Wright NM; Goss GD
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S247-S264. PubMed ID: 31857949
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation.
Zhang H; Xie R; Ai-Furas H; Li Y; Wu Q; Li J; Xu F; Xu T
ACS Med Chem Lett; 2022 Feb; 13(2):278-283. PubMed ID: 35178183
[TBL] [Abstract][Full Text] [Related]
35. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
37. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.
Costa DB; Kobayashi SS
Transl Lung Cancer Res; 2015 Dec; 4(6):809-15. PubMed ID: 26798593
[TBL] [Abstract][Full Text] [Related]
38. Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFR
Xu S; Zhou Z; He J; Guo J; Huang X; An Y; Pan Q; Xu S; Zhu W
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300460. PubMed ID: 38009481
[TBL] [Abstract][Full Text] [Related]
39. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.
Zhang H
Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501
[TBL] [Abstract][Full Text] [Related]
40. Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Lee C; Kim M; Kim DW; Kim TM; Kim S; Im SW; Jeon YK; Keam B; Ku JL; Heo DS
Cancer Res Treat; 2022 Jan; 54(1):140-149. PubMed ID: 33940786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
